NCT04710576 2026-03-16AGAVE-201Syndax PharmaceuticalsPhase 2 Active not recruiting241 enrolled 11 charts 1 FDA
NCT04301778 2026-03-13Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic CholangiocarcinomaSidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 Completed5 enrolled 13 charts
NCT06523556 2026-03-13Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic LeukemiaOhio State University Comprehensive Cancer CenterPhase 1/2 Recruiting52 enrolled